Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Yimer, Getnet ^a,b   Aderaye, Getachew ^b   Amogne, Wondwossen ^b   Makonnen, Eyasu ^b   Aklillu, Eleni ^c   Lindquist, Lars ^c   Yamuah, Lawrence ^a   Feleke, Beniyam ^d   Aseffa, Abraham ^a  

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c KAROLINSKA INSTITUTE   (Sweden)

^d St Peter Specialized TB Hospital   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMOXICILLIN; AMPICILLIN; ANTACID AGENT; CODEINE PHOSPHATE; COTRIMOXAZOLE; ETHAMBUTOL; GENTAMICIN; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; KETOCONAZOLE; PHENOBARBITAL; PROMETHAZINE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; ETHIOPIA; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; JAUNDICE; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT MONITORING; PREVALENCE; PROGNOSIS; RETREATMENT; RISK FACTOR; SPUTUM SMEAR; TUBERCULOSIS; ADOLESCENT; AGED; COHORT ANALYSIS; MIDDLE AGED; SERODIAGNOSIS; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; ETHIOPIA; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 46349111356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001809     Document Type: Article

References (31)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282: 677-686.
2. Yepes JF, Sullivan J, Pinto A (2004) Tuberculosis: medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98: 267-273.
3. Brewer TF, Heymann J (2004) To control and beyond: moving towards eliminating the global tuberculosis threat. J Epidemiol Community Health 58: 822-825.
4. Aaron L, Saadoun D, Calatroni I, Launay O, Emain N, et al. (2004) Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 10: 388-398.
5. Bassey EB, Momoh MA, Imadiyi SO, Udofia EB, Miri FS, et al. (2005) The trend of pulmonary tuberculosis in patients seen at DOTS clinics in the Federal Capital Territory, Abuja, Nigeria. Public Health 119: 405-408.
6. Gooze L (2003) Tuberculosis and HIV. Current American Thoracic Society/ CDC Treatment Recommendation.
7. Focus/disease watch (2004) Tuberculosis. Nature reviews/microbiology 2: 930-932.
8. WHO (2004) TB/HIV A CLINICAL MANUAL.
9. Ali J (1996) Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem. Postgrad Med 99: 217-220, 230-231, 235-236.
10. Cheuk-ming T (2002) MONITORING FOR HEPATOTOXICITY DURING ANTITUBERCULOSIS TREATMENT.
11. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, et al. (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37: 924-930.
12. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK (2002) Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166: 916-919.
13. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, et al. (1998) Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 157: 1871-1876.
14. Bruchfeld J, Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Kallenius G, et al. (2000) Sputum concentration improves diagnosis of tuberculosis in a setting with a high prevalence of HIV. Trans R Soc Trop Med Hyg 94: 677-680.
15. Kimmoun E, Samuel D (2002) Antituberculous drugs in patients with chronic liver disease. J Gastroenterol Hepatol 17: S408-S412.
16. Barnes PF, Barrows SA (1993) Tuberculosis in the 1990s. Ann Intern Med 119: 400-410.
17. Campos-Franco JA, Gonzalez-Quintela, Alende-Sixto MR (2004) Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. Eur J Intern Med 15: 396-397.
18. Ozick LA, Jacob L, Comer GM, Lee TP, Ben-Zvi J, et al. (1995) Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 90: 1978-1980.
19. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, et al. (1999) Distribution and concordance of N-acctyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8: 683-692.
20. Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, et al. (2004) Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. Braz J Infect Dis 8: 211-216.
21. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477.
22. Pol S, Lebray P, Vallet-Pichard A (2004) HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms. Clinical Infectious Diseases 38: 65-72.
23. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi B, et al. (2007) Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci 23: 33-38.
24. Huffmann C, Rockstroh JK, Kamps BS. HIV Medicine 2006. 2006: p. 395-480.
25. WHO (2006) antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach.
26. Shakya R, Rao BS, Shrestha B (2006) Evaluation of risk factors for antituberculosis drugs-induced hepatotoxicity in Nepalese population. Kathmandu university journal of science, engineering and technology II: 1-8.
27. Anand A, Seth AK, Paul M (2006) Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. MJAFI 62: 45-49.
28. Koju D, Rao BS, Shrestha B, Shakya R, Makaju R (2005) Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under dots treatment. Kathmandu university journal of science, engineering and technology 1(1).
29. Sturgill MG, Lambert GH (1997) Xenobiotic-induced hepatotoxicity. mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem 430: 1512-1526.
30. Pan L, Jia Z, Chen L, Fu E, Li G (2005) Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol 11: 2518-2521.
31. Lee BH, Koh W, Choi MS, Suh GY, Chung MP, et al. (2005) Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy. Chest 127: 1304-1311.